Joint Programming Initiative on Antimicrobial Resistance




Antibiotics have saved millions of lives. However, antimicrobial resistance (AMR) continues to spread, as over-use and misuse is rendering many antibiotics ineffective. By 2050, 10 million people each year are predicted to die as a result of drug resistant infections. Currently, there few new antibiotics in development. Therefore, we must focus on reducing the incidence of bacterial infectious disease, ensuring rational use of the remaining antibiotics and reducing transmission of resistant bacteria. We must also undertake further research to better understand how resistance develops and spreads in the environment. We also need to develop diagnostic tools and better surveillance methods as well as validating smarter strategies for using antibiotics in healthcare and agriculture.

The Joint Programming Initiative on Antimicrobial Resistance, JPIAMR, coordinates national funding and supports collaborative action for filling knowledge gaps on AMR. By mobilising existing and new resources, this initiative develops a critical mass and attracts new researchers to the AMR field. Our Strategic Research Agenda outlines the key areas to address and provides guidance documents for countries to align their AMR research agendas nationally and internationally.

As resistant bacteria do not observe national borders, JPIAMR works on an international level. By engaging nations beyond Europe as members, the JPIAMR platform enables collaborative actions in areas of unmet needs.

JPIAMR´s main ambition is to reduce AMR by supporting scientific activities at international level. This will offer evidence-based solutions at policy, public health and veterinarian/agricultural levels.


 KEY ACHIEVEMENTS: Aligning resources by developing a collaborative platform and maximising existing and future efforts to combat AMR.

Highlights include:

  • Adopting a ‘One Health’ approach with a Strategic Research Agenda and an Implementation Plan. This approach is also the basis for development of the WHO Global AMR Research Agenda;
  • Mapping AMR research and associated investment in participating countries was performed and published as an article in ‘The Lancet’. Member countries enjoyed a strong structural effect from having a national overview of their AMR research capacity, with results available online on an AMR projects database. JPIAMR also conducts several high-level policy events, three international conferences and twelve strategic workshops;
  • Developing AMR national alignments (via one health national expert panels and intergovernmental mirror groups) and AMR plans and strategies (from two countries with plans to twenty-two countries today) and adopting national plans to match the joint Strategic Research Agenda;
  • Funding research that both makes an impact and adds value. The commitment of up to €55 million of funding for four joint transnational calls during the period of 2014‐2016 was secured with four joint calls. These included a Research Network programme and one Eranet co-fund. Three further joint calls, including a fellowship programme, are in the pipeline;
  • Coordinating research priorities and calls with the EC, IMI and the pharmaceutical industry, through a dedicated working group, regular meetings and joint workshops, and
  • JPIAMR is an international platform, extending its membership beyond Europe. Japan, Argentina and Canada have joined. It is engaging with international stakeholders including WHO, the US National Institute of Health (NIH) and Transatlantic Taskforce on Antimicrobial Resistance (TAFTAR) organisations, the Association of Southeast Asian Nations (ASEAN) and the G7. JPIAMR activities are included in the G7 and G20 AMR declarations, in the WHO AMR Global Action Plan and in the latest UN AMR resolution.

JPIAMR has currently 23 members countries

Please select the individual countries to reach the member country web pages.

European Commission (DG Research) is a non voting member.